The effects of 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) infusion in type two diabetes patients

The effects of intravenous 5-aminoimidazole-4-carboxamide ribonucleoside (AICAR) infusion on glucose and fat metabolism in type two diabetes

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN31384581

Enrollment

Registered

2008-06-13

Start date

2006-06-01

Completion date

Unknown

Last updated

2021-01-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type two diabetes mellitus Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Interventions

Each subject participates in two experimental tests

one test in which AICAR (0.75 mg/kg/min) is infused and one test in which only saline (0.9% NaCl) is infused to ensure equal volume administration. The trial consists of two test days separated by at

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Type two diabetes patients 2. Male 3. Aged 45 - 65 years

Exclusion criteria

Exclusion criteria: 1. Renal or liver dysfunction 2. Gout 3. Exogenous insulin therapy

Design outcomes

Primary

Measure	Time frame
Tracer kinetics (rate of appearance and rate of disappearance) of glucose and free fatty acids. During both test days, outcomes were measured at the following timepoints: t = 0, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195 and 210 minutes.	—

Secondary

Measure	Time frame
Plasma concentrations of: 1. Glucose 2. Free fatty acids (FFA) 3. Insulin 4. Lactate 5. Triglycerides 6. Free glycerol During both test days, outcomes were measured at the following timepoints: t = 0, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, 180, 195 and 210 minutes.	—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026